Results 71 to 80 of about 682 (125)

Masthead: (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
wiley   +1 more source

Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect

Acta Pharmaceutica Sinica B
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homing anti-SARS-CoV-2 drug in treating COVID-19 patients.
Ning Sheng, Rui Li, Yang Li, Zhe Wang, Lulu Wang, Yuhuan Li, Jinlan Zhang, Jiandong Jiang   +7 more
openaire   +3 more sources

Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis

Frontiers in Pharmacology
Objective Azvudine (FNC), an antiviral drug approved in China for the treatment of Coronavirus disease 2019 (COVID-19) infection, has not yet established a well-defined safety profile in patients with renal impairment. This study aimed to evaluate the safety of using FNC in patients with renal impairment.
Xiaomin Zhang, Jiajian Qian, Jiawen Cui, Yuhong Luo, Sichao Huang, Zhiyong Wen   +5 more
openaire   +1 more source

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis

Infection and Drug Resistance
Siqin Zhang,1,* Songsong Tan,1,* Bin Yang,2 Yaoyao Wu,3 Guohang Yuan,3 Fengjiao Chen,4 Lin Liu3,5 1Department of Endocrinology and Metabolism, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, People’s Republic of China; 2Department
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L   +6 more
doaj  

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19

Journal of Infection, 2023
Yuan Gao, Zujin Luo, Shan Ren, Zhonghui Duan, Ying Han, Huihang Liu, Ziwen Gao, Xinyu Zhang, Zhongjie Hu, Yingmin Ma   +9 more
openaire   +2 more sources

The first Chinese oral anti-COVID-19 drug Azvudine launched

The Innovation, 2022
Bin Yu, Junbiao Chang
openaire   +2 more sources

A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes. [PDF]

Sci Rep
Zhu Z, Chen Q, Wang Z, Chen Q, Li X, Liu Y, Lu H, Feng J, Xie M, Dong X, Chen B, Huang J, Zeng X, Zeng Z, Yuan Y, Xu F, Liao X, Liang B, Chen W.   +18 more
europepmc   +1 more source

Commentary: A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes. [PDF]

Front Endocrinol (Lausanne)
Guo S, Zhang J, Shu J.
europepmc   +1 more source

The efficacy of azvudine in treating hospitalized COVID-19 patients: a retrospective single-center cohort analysis. [PDF]

J Thorac Dis
Lei H, Ye YW, Zhou YJ, Mao YF, Fang Y, Chen PP, You WW, Li S, Xu YY.   +8 more
europepmc   +1 more source

Association of Azvudine with severe outcomes among hospitalized patients with COVID-19 during an omicron-dominance period in Wuhan, China: a single-center, retrospective, matched cohort study. [PDF]

BMC Infect Dis
Guo Z, Li W, Wang K, Lu Y, Gao S, Wang X, Zhao Y, Zhai Z, Chen B, Sun F, Zhao S, Cheng H.   +11 more
europepmc   +1 more source